Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC

Video

Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.

Ruth Aiwu He, MD, PhD, scientific lead in liver and biliary cancers at Georgetown-Lombardi Comprehensive Cancer Center, discusses the results of the LEGACY study in patients with hepatocellular carcinoma (HCC).

The LEGACY study was a retrospective analysis of patients with early-stage HCC who received Y-90 glass microspheres (TheraSphere), according to He. In the overall cohort, Y-90 demonstrated a best overall response rate of 88%, with a complete response rate of 83%, says He.

Additionally, the therapy resulted in prolonged disease control, and the 3-year overall survival rate in patients with transplant or resection following Y-90 was 93%, says He. Overall, the results of the study appear to be quite promising, He concludes.

Related Videos
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,
John Michael Bryant, MD,
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic
Efrat Dotan, MD, Fox Chase Cancer Center
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers
Zev A. Wainberg, MD
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers